PSA Doubling Time (PSADT) Calculator
Calculates rate of PSA doubling in prostate cancer.
CreatorInstructions
Use in patients with prostate cancer who have undergone radical prostatectomy or definitive radiation therapy and have biochemical recurrence, defined as confirmed PSA ≥0.2 ng/mL after radical prostatectomy or a confirmed PSA rise of ≥2 ng/mL above the nadir PSA level after radiation therapy.
For patients with biochemical recurrence of prostate cancer, optimal calculation should include all PSA values obtained within 2 years of initially documented PSA recurrence.
Use at least 3 PSA values obtained over an interval of at least 3 months, ideally from the same laboratory/assay, to improve the reliability of the doubling-time estimate.
Entering more values improves the accuracy of the estimation.
Exclude PSA values obtained shortly after a treatment change (e.g., initiation or discontinuation of androgen deprivation therapy [ADT]) that could confound the true kinetics of recurrence.
Confirm castrate testosterone (<50 ng/dL) before using PSADT to guide treatment decisions in the castration-resistant setting; a rapidly rising PSA in a patient not confirmed to be castrate may reflect testosterone recovery rather than true castration resistance.
First (earliest) available PSA result
Min 0.01 – Max 10000
Introduction
The PSA doubling time (PSADT) estimates how many months it takes for a man’s PSA level to double. It’s used mainly after treatment for prostate cancer, such as surgery (radical prostatectomy) or radiation. After successful treatment, PSA should stay very low or undetectable. When it starts rising again, called biochemical recurrence, how fast it rises matters. A short doubling time suggests more active cancer, while a long doubling time often reflects slow-growing disease that may never cause problems. The PSADT is used to judge risk and help decide whether and when to start more treatment, scans, or careful monitoring. It’s also used in other situations, such as monitoring men on active surveillance or advanced prostate cancer. Use in patients with prostate cancer who have undergone radical prostatectomy or definitive radiation therapy and have biochemical recurrence, defined as confirmed PSA ≥0.2 ng/mL after radical prostatectomy or a confirmed PSA rise of ≥2 ng/mL above the nadir PSA level after radiation therapy.
In patients with biochemical recurrence, this tool helps:
Predict the risk of metastasis and risk of dying of prostate cancer when combined with other factors, such as the Gleason Score and length of time to biochemical recurrence.
Identify patients more likely to develop clinically significant disease.
Guide patient selection for salvage local therapy or ADT.
Guide use and timing of imaging studies.
What it needs
Two to five PSA results (ng/mL) with the date of each test. The values should be in order over time, ideally from the same lab, since different lab methods can give slightly different results. PSA entries should be increasing over time.
For patients with biochemical recurrence of prostate cancer, optimal calculation should include all PSA values obtained within 2 years of initially documented PSA recurrence.
Use at least 3 PSA values obtained over an interval of at least 3 months, ideally from the same laboratory/assay, to improve the reliability of the doubling-time estimate.
Entering more values improves the accuracy of the estimation.
Exclude PSA values obtained shortly after a treatment change (e.g., initiation or discontinuation of androgen deprivation therapy [ADT]) that could confound the true kinetics of recurrence.
Confirm castrate testosterone (<50 ng/dL) before using PSADT to guide treatment decisions in the castration-resistant setting; a rapidly rising PSA in a patient not confirmed to be castrate may reflect testosterone recovery rather than true castration resistance.
How it’s calculated
Prostate-specific antigen doubling time (PSADT) = ln(2) / x,
Where x = slope of the relationship between ln(PSA, ng/mL) and time of PSA measurement (i.e., ln(PSAn) - ln(PSA1) / time between PSAn and PSA1, where n refers to a measurement >1)
Results & Considerations
Slope: Average rate of change in the natural log of PSA per month, fitted across all the PSA values entered.
PSADT: Estimated time for the PSA level to double, based on all the PSA values entered.
Shorter PSADT reflects faster increase in PSA levels, while longer PSADT reflects a slower increase in PSA levels over time.
Results ought to be interpreted alongside the Gleason Score, time to biochemical recurrence and disease extend. Consider all relevant factors, such as age, comorbidities, life expectancy and patient preferences in management strategies.
Consult the NCCN Guidelines for more information.
All questions & possible results
PSA measurementsTitle not visible
PSA₁
First (earliest) available PSA result
A number between 0.01 and 10000, in ng/mL.
PSA₂
Second available PSA result
A number between 0.01 and 10000, in ng/mL.
Time between PSA₁ and PSA₂ measurement
A number between 0.1 and 600, in months or days.
Add another measurement
Select one option:
- Yes
- No
PSA₃
Third available PSA result
A number between 0.01 and 10000, in ng/mL.
Time between PSA₂ and PSA₃ measurement
A number between 0.1 and 600, in months or days.
Add a 4th measurement
Select one option:
- Yes
- No
PSA₄
Fourth available PSA result
A number between 0.01 and 10000, in ng/mL.
Time between PSA₃ and PSA₄ measurement
A number between 0.1 and 600, in months or days.
Add a 5th measurement
Select one option:
- Yes
- No
PSA₅
Fifth available PSA result
A number between 0.01 and 10000, in ng/mL.
Time between PSA₄ and PSA₅ measurement
A number between 0.1 and 600, in months or days.
Possible results
PSA slope
Average rate of change in the natural log of PSA per month, fitted across all the PSA values entered.
PSA doubling time
Estimated time for the PSA level to double, based on all the PSA values entered.
Shorter PSADT reflects faster increase in PSA levels, while longer PSADT reflects a slower increase in PSA levels over time.
Results ought to be interpreted alongside the Gleason Score, time to biochemical recurrence and disease extend. Consider all relevant factors, such as age, comorbidities, life expectancy and patient preferences in management strategies.
Consult the NCCN Guidelines for more information.
PSA value should be increasing over time
One or more PSA values entered are not higher than the previous PSA entry. Please check the values and the order they were entered in.
Citation
Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural History of Progression After PSA Elevation Following Radical Prostatectomy. JAMA. 1999;281(17):1591–1597.
Literature
Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural History of Progression After PSA Elevation Following Radical Prostatectomy. JAMA. 1999;281(17):1591–1597.
https://jamanetwork.com/journals/jama/fullarticle/189741Patel A, Dorey F, Franklin J, deKernion JB. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol. 1997 Oct;158(4):1441-5.
https://pubmed.ncbi.nlm.nih.gov/9302139/Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005 Jul 27;294(4):433-9.
https://pubmed.ncbi.nlm.nih.gov/16046649/National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 3.2024. National Comprehensive Cancer Network; 2024.
https://www.nccn.org/guidelines/category_1#prostate
- Creator
Dr. Charles R. Pound, MDChief of urology in the department of surgery at the University of Mississippi Medical Center in Jackson, MS. Professor of medicine at the University of Mississippi School of Medicine.
- Provided by
EVAL Foundation
- Contributor · Reviewer
Jennifer Glen, DNP, FNP-BCEVAL Health, Chief Medical Officer EVAL Foundation